Cargando…
Omicron subvariants illustrate reduced respiratory tissue penetration, cell damage and inflammatory responses in human airway epithelia
INTRODUCTION: To explore whether the reported lower pathogenicity in infected individuals of variant of concern (VoC) Omicron and its current subvariants compared to VoC Delta may be related to fundamental differences in the initial virus-tissue interaction, we assessed their ability to penetrate, r...
Autores principales: | Zaderer, Viktoria, Abd El Halim, Hussam, Wyremblewsky, Anna-Lena, Lupoli, Gaia, Dächert, Christopher, Muenchhoff, Maximilian, Graf, Alexander, Blum, Helmut, Lass-Flörl, Cornelia, Keppler, Oliver T., Huber, Lukas A., Posch, Wilfried, Wilflingseder, Doris |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10616953/ https://www.ncbi.nlm.nih.gov/pubmed/37915577 http://dx.doi.org/10.3389/fimmu.2023.1258268 |
Ejemplares similares
-
Antiviral drugs block replication of highly immune-evasive Omicron subvariants ex vivo, but fail to reduce tissue inflammation
por: Dichtl, Stefanie, et al.
Publicado: (2023) -
Salivary antibodies induced by BA.4/BA.5-convalescence or bivalent booster Immunoglobulin vaccination protect against novel SARS-COV-2 variants of concern
por: Diem, Gabriel, et al.
Publicado: (2023) -
ColdZyme® protects airway epithelia from infection with BA.4/5
por: Viktoria, Zaderer, et al.
Publicado: (2022) -
Correction: ColdZyme® protects airway epithelia from infection with BA.4/5
por: Zaderer, Viktoria, et al.
Publicado: (2023) -
SARS-CoV-2–infected primary human airway epithelia illustrate mucus hypersecretion
por: Posch, Wilfried, et al.
Publicado: (2021)